Stay updated with breaking news from Dcph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.03, MarketWatch Earnings reports. Deciphera Pharmaceuticals had a negative return on equity of 48.99% and a negative net margin of 127.92%. The firm […]
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price increased by Stifel Nicolaus from $20.00 to $22.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 88.68% from the company’s current price. DCPH has […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) CEO Steven L. Hoerter sold 21,573 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $12.02, for a total value of $259,307.46. Following the sale, the chief executive officer now owns 40,927 shares in the company, […]
DCPH | Complete Deciphera Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
By Dean Seal Deciphera Pharmaceuticals said the Phase 3 study of its treatment vimseltinib for tenosynovial giant cell tumors met its primary endpoint and...